Irritable Bowel Syndrome Clinical Trial
Official title:
Endogenous Pain Processing and Effectiveness of Pain Neuroscience Education in Children With Functional Abdominal Pain and Irritable Bowel Syndrome
The primary scientific objective of the study entails examining whether altered endogenous pain inhibition is present in children with functional abdominal pain (FAP) and irritable bowel syndrome (IBS) compared with healthy controls (Part 1). A secondary objective implies examining whether pediatric pain neuroscience education (PNE) is able to improve pain catastrophizing, pain-related fear, pain intensity (including symptoms and indices of central sensitization) and pain-related functional disability in children with FAP or IBS (Part 2).
Abdominal pain-related functional gastrointestinal disorders (AP-FGIDs) are common in
children, showing a prevalence of 13.5% in Western populations and developing countries.
Gastrointestinal disorders are categorised within the Rome criteria III, with irritable bowel
syndrome (IBS) (65%) and functional abdominal pain (FAP) (35%) as most commonly occurring
subtypes, followed by FAP syndrome, functional dyspepsia and abdominal migraine. These
numbers call for action, knowing that persistent pain periods associated with AP-FGIDs
significantly interferes with a child's daily functioning. Children suffering from AP-FGIDs
participate less during recreational activities, show difficulties in maintaining social
contacts, are more absent at school and express academic impairments. Additionally, they
report decreased health related quality of life and need more health care utilization.
To date, the pathogenesis underlying AP-FGIDs in children remains unclear. Previous studies
suggested abnormal brain-gut interaction, altered gut motility, visceral hypersensitivity,
psychosocial disturbance and immune activation as possible explanations for the symptoms. In
accordance to research in adults with FGIDs evidence is even growing for the contribution of
central sensitization (CS) in the development or persistence of AP-FGIDs in children. CS is
defined as "an amplification of neural signalling within the central nervous system that
elicits pain hypersensitivity" or "increased responsiveness of nociceptive neurons in the
central nervous system to their normal or subthreshold afferent input". This process
encompasses malfunctioning of descending inhibitory nociceptive pathways which result in
dysfunctional endogenous analgesic control and increased activity of descending nociceptive
facilitation and overactivity of the pain neuromatrix in the brain. A systematic review
addressing the contribution of CS in pediatric chronic pain conditions concluded that
manifestations such as somatic hyperalgesia and altered central pain processing in children
with recurrent abdominal pain disorders (RAP) and deficient descending inhibitory nociceptive
processing in girls with irritable bowel syndrome (IBS) are indicative of CS in some subtypes
of AP-FGIDs (review in progress). However, given the heterogeneous study populations,
different protocols and methods used to objectify the presence of CS in this review, no clear
statement could be made. In addition, no study examining descending inhibitory nociceptive
processing in children with FAP was found.
Descending inhibitory nociceptive processing might be dysfunctional in children with FAP and
IBS. Anyhow, research demonstrated that this manifestation of CS can be further influenced by
the child's characteristics. Behavioural responses, emotional and cognitive aspects are
involved in the facilitation of sensitization through an increased cerebral activation of
limbic structures, the insula and large areas of the frontal, temporal and parietal cortices,
resulting in a diminished inhibition of the descending pathways.
Parental behaviours may also play an important role in the child's adjustment to pain.
Parents are considered essential participants in the management of their child's pain, as
parental attitudes, responses, and beliefs can influence the child's pain and adherence to
treatment. Indeed, both parental solicitous behaviours (e.g., according special privileges to
the child) and parental discouraging behaviours (e.g., criticizing the child) have been found
to be associated with increased functional disability. Further, evidence suggests that
children's own pain beliefs and pain coping skills may be modelled after their parents'
(maladaptive) pain beliefs and pain coping skills. Additionally, increased levels of parent
emotional distress have been linked to higher levels of child functional disability and
self-reported pain. This underscores the importance of including parents in the assessment
and treatment of pediatric chronic pain for optimal outcomes.
Negative cognitions of both the parents and the child can develop when they do not understand
the origin of the FAP or IBS. Based on the premise that a better understanding of the nature
of the illness results in improved patient outcomes, both child and parents should be
addressed by education. Given the possible contribution of CS in children with FAP or IBS,
education should include explanation and reassurance about the cause of pain, a brief summary
of relevant pain mechanisms and the integral role of psychosocial and physical factors in
precipitating and maintaining pain. This main content can be given by pain neuroscience
education (PNE). PNE has been studied in various adult chronic pain populations and has shown
to be effective in changing pain beliefs and improving health status as well as pain coping
strategies.
In contrast to a traditional model of tissue injury or nociception and pain, PNE aims to
describe how the nervous system interprets information from tissues through peripheral nerve
sensitization, central sensitization, synaptic activity and brain processing. It also
explains how neural activation, as either upregulation or downregulation, has the ability to
modulate the pain experience in response to (or in absence of) nociceptive input. Patients
are thus educated that the nervous system's processing of their injury, in conjunction with
various psychosocial aspects, determines their pain experience and that pain is not always a
true representation of the status of the tissues. Up to recently, no studies have examined
the benefits of PNE in the context of pediatric chronic pain. Drawing upon available evidence
in adult samples, it is expected that PNE provided to children will lead to beneficial child
pain-related outcomes. Involving parents in PNE sessions will facilitate increased parental
understanding of biopsychosocial factors that influence their child's pain, as well as learn
how they can support their child to manage symptoms.
Concrete, the present study will examine (1) the function of descending inhibitory
nociceptive processing in children with FAP or IBS compared to healthy children (Part 1) and
whether (2) reconceptualization of pain, by PNE, is able to influence pain catastrophizing,
pain-related fear, pain intensity (including symptoms and indices of central sensitization)
and pain-related functional disability (Part 2).
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03720314 -
Microbiota Profiling in IBS
|
||
Recruiting |
NCT06166563 -
Exercise, Irritable Bowel Syndrome and Fibromyalgia
|
N/A | |
Completed |
NCT05213910 -
Study of a Management Strategy of Functional Bowel Disordes Related to Irritable Bowel Syndrome (IBS) With a Mixture of 8 Microbiotic Strains
|
N/A | |
Recruiting |
NCT05985018 -
Traditional Dietary Advice Vs. Mediterranean Diet in IBS
|
N/A | |
Completed |
NCT04486469 -
Efficacy of Physiotherapy Techniques on Irritable Bowel Syndrome (IBS). Pilot Study.
|
N/A | |
Completed |
NCT06407609 -
Positive Outcomes of the Supplementation With Lecithin-based Delivery Form of Curcuma Longa and of Boswellia Serrata in IBS
|
N/A | |
Completed |
NCT04656730 -
Effect of STW5 (Iberogast ®) and STW5-II (Iberogast N®) on Transit and Tolerance of Intestinal Gas
|
Phase 4 | |
Completed |
NCT04145856 -
Combination of Alverine-simeticone and i3.1 Probiotic in IBS-D and IBS-M in Mexico
|
Phase 4 | |
Recruiting |
NCT04138225 -
The Ecological Role of Yeasts in the Human Gut
|
||
Active, not recruiting |
NCT03586622 -
One Year Home Monitoring and Treatment of IBS Patients
|
N/A | |
Completed |
NCT05207618 -
Utility of the Administration of Chesnut and Quebracho Extract for Irritable Bowel Syndrome Diarrhea Predominant
|
N/A | |
Not yet recruiting |
NCT06369753 -
Visible Abdominal Distension
|
N/A | |
Not yet recruiting |
NCT05157867 -
In Vivo Effects of Amylase Trypsin Inhibitors
|
N/A | |
Not yet recruiting |
NCT05100719 -
The Role of Irritable Bowel Syndrome in Lactose Intolerance (LION)
|
N/A | |
Recruiting |
NCT05001997 -
Effects of Lactose-free Dairy Products on Athletes With Irritable Bowel Syndrome
|
N/A | |
Recruiting |
NCT02953171 -
Probiotics in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT02977975 -
Lacto-fermented Sauerkraut in the Treatment of Irritable Bowel Syndrome
|
N/A | |
Completed |
NCT03266068 -
Epidemiology and Pathophysiology of Post-Infectious Functional GI Disorders
|
||
Completed |
NCT02980406 -
The Role of FODMAPs in Upper GI Effects, Colonic Motor Activity and Gut-brain Signaling at the Behavioral Level
|
N/A | |
Completed |
NCT03318614 -
Bifidobacterium Infantis M-63 Improves Mental Health in Irritable Bowel Syndrome Developed After a Major Flood Disaster
|
Phase 2/Phase 3 |